Securities code: Nanhua Bio-Medicineco.Ltd(000504) securities abbreviation: Nanhua Bio-Medicineco.Ltd(000504) Announcement No.: 2022018 Nanhua Bio-Medicineco.Ltd(000504)
Announcement of abnormal fluctuations in stock trading
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Introduction to abnormal fluctuations in stock trading
Nanhua Bio-Medicineco.Ltd(000504) (hereinafter referred to as “the company”) stock (Securities abbreviation: Nanhua Bio-Medicineco.Ltd(000504) , securities code: Nanhua Bio-Medicineco.Ltd(000504) ) in three consecutive trading days on March 3, 2022, March 4, 2022 and March 7, 2022, the cumulative deviation of the closing price from the value exceeds 20%. According to the relevant provisions of the trading rules of Shenzhen Stock Exchange, it belongs to the situation of abnormal stock fluctuation.
2、 The company pays attention to and verifies the situation
In view of the abnormal fluctuation of the company’s stock trading, the company has checked the relevant matters and explained the conditions affecting the abnormal fluctuation of the company’s stock as follows:
1. The company has not found any information disclosed in the previous period that needs to be corrected or supplemented;
2. The company has not found any unpublished material information that may or has had a great impact on the company’s stock trading price reported by the public media recently;
3. The operation of the company is normal, and the internal and external business environment has not changed significantly;
4. After verification, the company, the controlling shareholder and the actual controller have no major matters that should be disclosed but not disclosed by the company;
5. After verification, the controlling shareholders and actual controllers did not buy or sell the company’s shares during the abnormal fluctuation of stock trading.
3、 Whether there is a description of the information that should be disclosed but not disclosed
The board of directors of the company confirms that, in addition to the above matters, the company has no undisclosed matters that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange or planning, negotiation, intention, agreement, etc. related to the matters; The board of directors has not been informed that the company has undisclosed information that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and has a great impact on the trading price of the company’s shares and their derivatives.
4、 Risk tips
1. Through self-examination, the company does not violate the fair disclosure of information;
2. The company disclosed the performance forecast for 2021 (Announcement No.: 2022011) on January 29, 2022. The net profit loss attributable to the shareholders of the listed company in 2021 was 13.5-16.5 million yuan, a decrease of 265.55% – 302.34% over the same period of the previous year, and the net profit loss after deducting non recurring profits and losses was 21.5-24.5 million yuan, a decrease of 480.22% – 533.28% over the same period of the previous year. There is no need to amend the above performance forecast;
3. The company solemnly reminds investors: China Securities News, Securities Daily, securities times, Shanghai Securities News and cninfo (www.cn. Info. Com. CN.) As the information disclosure media designated by the company, all information publicly disclosed by the company shall be subject to the information published in the above designated media. Investors are invited to invest rationally and pay attention to risks.
It is hereby announced.
Nanhua Bio-Medicineco.Ltd(000504) board of directors March 8, 2022
